Prediction of Novel Anoctamin1 (ANO1) Inhibitors Using 3D-QSAR Pharmacophore Modeling and Molecular Docking

Yoon Hyeok Lee, Gwan‐Su YiInternational Journal of Molecular Sciences 2018 · DOI

TL;DR

This paper presents a computational approach to discover novel inhibitors for Anoctamin1 (ANO1), a crucial calcium-activated chloride channel implicated in various diseases. By developing a robust 3D-QSAR pharmacophore model and employing molecular docking, the researchers identified two promising natural product-derived compounds as potential ANO1 inhibitors, offering a new avenue for drug development.

What Problem Does This Paper Address?

Anoctamin1 (ANO1) is a vital protein involved in numerous physiological processes, making it a promising drug target for conditions like cancer, pain, and asthma. While some ANO1 inhibitors have been found through high-throughput screening, the discovery of potent and specific inhibitors remains challenging. A significant hurdle is the lack of structural information for ANO1, which historically limited structure-based drug design. This paper aims to bridge this gap by developing a computational model to predict and identify novel ANO1 inhibitors, addressing the need for more efficient and targeted drug discovery strategies.

Methods

The study employed a two-pronged computational approach:

  1. 3D-QSAR Pharmacophore Modeling: The researchers used the HypoGen algorithm in Discovery Studio to generate a pharmacophore model. This model represents the essential chemical features (hydrogen bond acceptor, hydrogen bond donor, hydrophobic, and ring aromatic) required for ANO1 inhibition. They trained this model using a dataset of 20 known ANO1 inhibitors and then validated it using a separate test set of 32 compounds, along with statistical methods like Fischer randomization and leave-one-out cross-validation.
  2. Molecular Docking: After generating a pharmacophore model (Hypo2) with high predictive power, the researchers performed virtual screening of the ZINC database. This screening identified 580 drug-like compounds with estimated activity below 100 nM. These hit compounds were then subjected to molecular docking using the Libdock algorithm against the ANO1 protein structure. This step helped to refine the candidates by assessing their binding affinity and interactions within the ANO1 active site.

Datasets

  • Training Set: 20 known ANO1 inhibitors with experimental IC50 values ranging from 0.107 to 29.2 µM.
  • Test Set: 32 known ANO1 inhibitors with experimental IC50 values, used for validating the pharmacophore model's predictive performance.
  • ZINC Database: A large chemical database containing 309,149 compounds, used for virtual screening to identify novel hit candidates.

Key Insights and Ideas

  • The Power of Pharmacophores: The study demonstrates that a well-constructed 3D-QSAR pharmacophore model can effectively capture the key features responsible for ANO1 inhibition, even in the absence of detailed structural information about the target protein.
  • Hypo2 as a Robust Model: The developed pharmacophore hypothesis, Hypo2, proved to be statistically robust and highly predictive, accurately estimating the activity of both training and test set compounds. This suggests its reliability for screening novel chemical entities.
  • Natural Products as Promising Leads: The identification of two novel lead candidates from natural product sources is particularly exciting. This highlights the potential of natural products as a rich source for discovering new drug scaffolds with unique properties.
  • Synergistic Approach: Combining ligand-based pharmacophore modeling with structure-based molecular docking proved to be a powerful strategy for filtering and prioritizing potential drug candidates, reducing false positives and increasing the likelihood of finding true inhibitors.

Key Results

  • Best Pharmacophore Model (Hypo2): Hypo2, comprising a hydrogen bond acceptor, a hydrogen bond donor, a hydrophobic feature, and a ring aromatic feature, was selected as the best model. It achieved a high correlation coefficient for the training set (r²training = 0.969) and an excellent correlation for the test set (r²test = 0.909).
  • Virtual Screening Success: Virtual screening of the ZINC database using Hypo2 yielded 580 drug-like candidates with estimated activity < 100 nM.
  • Novel Lead Candidates: Molecular docking identified two compounds (ZINC8643627 and ZINC225516955) as promising novel lead candidates. These compounds showed strong interactions with the calcium-binding site of ANO1.
  • Estimated Potency: The estimated activities for the lead candidates were 0.052 µM for ZINC8643627 and 0.092 µM for ZINC225516955, indicating high predicted potency.
  • Novelty: Interestingly, these two lead compounds were identified as natural products and had no prior reports of ANO1 inhibitory activity in the PubChem database, underscoring their novelty.

Limitations and Future Work

  • Limitations:
    • The study acknowledges that while the identified compounds show strong interactions with the calcium-binding site, further molecular dynamics simulations are needed to fully understand their binding mechanisms.
  • The authors also suggest that exploring other putative active sites on ANO1 might be beneficial.
  • The current study relies on computational predictions; experimental validation of the inhibitory activity and binding mechanism of the identified lead compounds is crucial.
  • Future Work:
    • Conducting experimental biological validation of the two identified lead candidates.
  • Performing molecular dynamics simulations to gain deeper insights into the binding modes and dynamics.
  • Investigating other potential binding sites on the ANO1 protein.
  • Utilizing the developed pharmacophore model for designing novel ANO1 inhibitors with improved potency and specificity.

Summary updated

Abstract

Recently, anoctamin1 (ANO1), a calcium-activated chloride channel, has been considered an important drug target, due to its involvement in various physiological functions, as well as its possibility for treatment of cancer, pain, diarrhea, hypertension, and asthma. Although several ANO1 inhibitors have been discovered by high-throughput screening, a discovery of new ANO1 inhibitors is still in the early phase, in terms of their potency and specificity. Moreover, there is no computational model to be able to identify a novel lead candidate of ANO1 inhibitor. Therefore, three-dimensional quantitative structure-activity relationship (3D-QSAR) pharmacophore modeling approach was employed for identifying the essential chemical features to be required in the inhibition of ANO1. The pharmacophore hypothesis 2 (Hypo2) was selected as the best model based on the highest correlation coefficient of prediction on the test set (0.909). Hypo2 comprised a hydrogen bond acceptor, a hydrogen bond donor, a hydrophobic, and a ring aromatic feature with good statistics of the total cost (73.604), the correlation coefficient of the training set (0.969), and the root-mean-square deviation (RMSD) value (0.946). Hypo2 was well assessed by the test set, Fischer randomization, and leave-one-out methods. Virtual screening of the ZINC database with Hypo2 retrieved the 580 drug-like candidates with good potency and ADMET properties. Finally, two compounds were selected as novel lead candidates of ANO1 inhibitor, based on the molecular docking score and the interaction analysis. In this study, the best pharmacophore model, Hypo2, with notable predictive ability was successfully generated, and two potential leads of ANO1 inhibitors were identified. We believe that these compounds and the 3D-QSAR pharmacophore model could contribute to discovering novel and potent ANO1 inhibitors in the future.
BibTeX
@article{lee2018prediction,
  author = {Yoon Hyeok Lee and Gwan‐Su Yi},
  title = {{Prediction of Novel Anoctamin1 (ANO1) Inhibitors Using 3D-QSAR Pharmacophore Modeling and Molecular Docking}},
  journal = {International Journal of Molecular Sciences},
  year = {2018},
  doi = {10.3390/ijms19103204},
}
Figure